VRTX acquires ALPN for $65/sh cash—a 67% premium to yesterday’s (unaffected) closing price: https://investors.vrtx.com/news-releases/news-release-details/vertex-enters-agreement-acquire-alpine-immune-sciences The nominal deal value is $4.9B.